Traders should monitor for upcoming earnings, potential downgrades, or corporate developments that may have prompted coordinated executive selling. Absent strong positive news, this level of selling by C-suite executives often precedes negative catalysts or reflects diminished confidence in near-term prospects.
How the stock moved after the report
⚠ Clustered BEARISH VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Feb 23 $3.75entry
- T+1 · 9mo ago +1.07%α +0.33% · $3.79
- T+5 · 9mo ago −4.80%α −5.42% · $3.57
- T+20 · 8mo ago −12.27%α −8.32% · $3.29
- T+60 · 6mo ago −6.67%α −14.92% · $3.50
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Ironwood Pharmaceuticals CEO Thomas McCourt and CFO Gregory Martini collectively sold over $821,000 worth of shares in open-market transactions over two days, with both executives selling significant blocks at prices between $3.66 and $3.81 per share. This represents a coordinated insider selling event involving the company's top two executives.
Key Financial Metrics
Key Facts
- CEO Thomas McCourt sold 198,283 shares for $739,929.33 in two transactions on Feb 23–24, 2026
- CFO Gregory Martini sold 21,944 shares for $81,888.09 in two transactions on same dates
- Total insider selling cluster: 220,227 shares, $821,817.42 total value
- All transactions were open-market sales (Form 4 code 'S'), not forced or tax-related
- Sales occurred at declining prices: $3.81 down to $3.66, suggesting possible urgency or lack of price sensitivity
Financial Impact
$821,817 in net insider selling over 7 days
Risk Factors
- Insider selling can signal lack of confidence in future stock performance
- Concentrated selling by both CEO and CFO increases negative perception risk
- Potential for downward price pressure if market interprets this as bearish signal
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CONTEXT: Insider Cluster Data (4 trades, 7d window) | cluster-IRWD-1772053905883 |
Track record
13 reports on IRWD
3 of 4 bullish or bearish reports moved the stock their way by T+20. Best: +20.35% at T+5 after the Nov 5, 2026 report. 5 of 5 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $4.88 Now $4.85 −0.51% settles Dec 15
- Nov 13, 20263d ago 144 Neutral 2/10 Entry $4.84 Now $4.85 +0.21% settles Dec 15
- Nov 10, 20266d ago SC 13G Neutral 3/10 Entry $4.81 Now $4.85 +0.83% settles Dec 9
- Nov 9, 20267d ago Institutional Cluster Neutral 3/10 Entry $4.81 Now $4.85 +0.83% settles Dec 9
- Nov 5, 202611d ago 8-K Bullish 6/10 Entry $4.03 Now $4.85 +20.35% settles Dec 4
- Oct 28, 202619d ago SC 13G/A Neutral 3/10 Entry $3.61 Now $4.85 +34.35% settles Nov 25
- Oct 16, 20264w ago 8-K Neutral 3/10 Entry $3.50 to $4.85 Now $4.85 +38.57% ▲ +38.57% +39.73% vs SPY
- Aug 6, 202614w ago 8-K Bullish 7/10 Entry $4.26 to $4.29 Now $4.85 +13.85% ▲ +0.70% +0.10% vs SPY
- May 13, 202626w ago 8-K Mixed 6/10 Entry $3.68 to $3.63 Now $4.85 +31.79% ▼ −1.36% −0.75% vs SPY
- May 7, 202627w ago 8-K Bullish 7/10 Entry $4.17 to $3.24 Now $4.85 +16.31% ▼ −22.30% −25.44% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers